Candida auris has caused nosocomial infections and transmissions within hospital settings. As little is known about the efficacy of skin and environmental decontamination products to kill C. auris, this study investigated the in vitro activity of chlorine, chlorhexidine, iodine povidone and vaporised hydrogen peroxide products against C. auris.
| INTRODUCTION
There has been an emergence of the multidrug-resistant yeast Candida auris (C. auris) causing a number of hospital outbreaks and nosocomial infections globally. [1] [2] [3] [4] [5] Patient to patient transmission has been documented leading primarily to extensive C. auris skin colonisation
and an increased risk of candidaemia. 2 It has been observed that the immediate environment of C. auris colonised patients becomes readily contaminated which may pose a reservoir contributing to nosocomial transmission. 2, 4 Our recent UK outbreak in a cardio-thoracic specialist centre has illustrated the challenges of preventing C. auris transmission and dealing with considerable environmental contamination. 2 The core Infection Prevention and Control (IPC) measures focused on skin decolonisation of C. auris-positive patients with chlorhexidine products and the decontamination of the hospital environment with chlorine-based reagents followed by hydrogen peroxide (H 2 O 2 )
vaporisation. However, to date there has been little published information on the efficacy of such disinfectants against C. auris and not very much is known about effective measures for the prevention and control of healthcare-associated C. auris infections and transmission. 6 We have therefore undertaken an in vitro evaluation of the efficacy of key disinfectants employed during our outbreak in killing C. auris which may help to guide the implementation of evidence-based IPC measures in the prevention and control of C. auris transmission in the healthcare setting.
| MATERIALS AND METHODS

| Fungal isolates
A total of 34 yeast isolates were studied. These included four Minimum inhibitory concentration (MIC) for each compound at each time point was defined as the lowest compound concentration at which no growth was observed (ie 100% inhibition). 
| Gas-vaporised hydrogen peroxide
F I G U R E 1
| RESULTS
| DISCUSSION
The recent global emergence of C. auris hospital outbreaks indicates the propensity of this yeast to cause nosocomial transmission within the healthcare setting. 1,2,4,6-10 During our outbreak investigation it has been established that C. auris can be found on many vertical surfaces within the immediate environment of colonised patients 2 and has the potential to remain viable on surfaces for 28 days. 11 The pathogen has also been found in medical equipment such as temperature probes.
12
We postulate that the environmental contamination is likely to originate from patients skin scale shedding and subsequent further spread due to contamination of equipment such as monitor, key pads, trolley and floor surfaces as described previously. 2, 11 The fact that patient's skin colonisation also carries a high risk of developing infections such as vascular line, surgical wound or urinary catheter infections with the potential of developing life threatening candidaemia makes effective skin decolonisation a major IPC strategy. A recent study demonstrating the ability of C. auris to form biofilms is supporting evidence for the need to prevent line colonisation and infection. 13 As there has been little published evidence to date on the efficacy of common skin disinfectants for the treatment of C. auris skin colonisation, we have undertaken in vitro studies to investigate two agents that were used in clinical practice during our outbreak, namely chlorhexidine and iodinated povidone. Our results demonstrate that C. auris is effectively inhibited by chlorhexidine solution in vitro at concentrations below the recommended use of 4% liquid chlorhexidine used for skin decolonisation. We therefore continued the use of such products for patient skin decolonisation and staff members' hand decontamination. Interestingly, in a previous study undertaken during an outbreak with C. albicans on an intensive care unit, a chlorhexidine gluconate 4% product did not sufficiently eradicate the outbreak strain during handwashing compared to C. albicans control isolates demonstrating that some outbreak strains may be more resilient.
14 During our outbreak, we also used 2% chlorhexidine-impregnated wash cloth as part of a routine skin wash for all intensive care patients. The product is designed to dry on the skin and not be washed off which means the effective components stay on the skin for a prolonged time. We therefore tested the wipes for 16 hours incubation before assessing inhibition of Candida growth in vitro. All our study results indicate that chlorhexidine has some efficacy in inhibiting C.
auris growth which is greater when exposed more than 3 minutes.
Concentrations of 2% currently used in clinical practice may, however, not show sufficient growth inhibition.
One observation during our outbreak was that once patients were C. auris skin colonised, daily washes with 2% chlorhexidine wash cloth did not consistently eradicate the pathogen. There may be a number of explanations for this such as the development of resistance due to prolonged use cannot be excluded or patients may also become re-colonised from their immediate environment (including bed linen, pillows, night ware, mattresses, etc.), although we never recovered the fungus from such sites. It is also unknown whether patient's skin may recolonise from mucosal gut colonisation or oral cavity. We are currently investigating the colonisation dynamics of C. auris in patients during the outbreak over time. In any case the use of higher concentrations above the manufacturers recommendations (>4%) are not advisable due to allergic reactions or toxicity. 15 Alternative disinfectants may need to be sought for effective longer term patient decontamination.
We also addressed the efficacy of iodinated povidone, a commonly used presurgical skin disinfectant. Our data showed that chlorhexidine was much less inhibitory at 3 minutes contact time compared to iodinated povidone used at 10% in clinical practice (2.6-fold vs 8-fold reduction in viability). Based on this observation, we implemented the use of 10% iodinated povidone for preoperative surgical skin preparation in C. auris colonised patients undergoing cardio-thoracic surgery.
On follow-up none of these patients developed a C. auris related infection postoperatively. More studies are needed to confirm our observation including quantitative suspension tests such as per European standard (EN13624:2013) for the evaluation of fungicidal activity of F I G U R E 3 Inhibition zones (mm) of 12 unique isolates of Candida auris (10 from UK outbreak and 2 from India) and four ATCC type strain isolates of Candida species measured against 1.00 × 5.00 cm strips of two skin antiseptic products impregnated with 2% CHG. All UK outbreak isolates of C. auris showed reduced inhibition against both Sage pad (A) and Clinell cloth (B) after 18-48 h incubation at 30 ± 2°C chemical disinfectants used for quality assurance by manufacturers. It would also be valuable to extend investigations to establish the efficacy of alcohol-based hand disinfectants which we did not test during this outbreak as our staff members' hand screening did not demonstrate any hand C. auris carriage.
Apart from the importance to reduce C. auris skin carriage in order to prevent infections, another major IPC measure during our outbreak control was the focus on cleaning and decontamination of the patient environment. We have previously demonstrated that vertical surfaces and medical equipment surrounding C. auris colonised patients becomes readily contaminated. Our study has focussed on the testing of compounds used for skin decolonisation and environmental decontamination during the suc- 
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